We are live on ! Find out more
BEAM icon

Beam Therapeutics
BEAM

214 hedge funds and large institutions have $1.82B invested in Beam Therapeutics in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $7.11M

18% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 62

8.14% more ownership

Funds ownership: 86.14% → 94.28% (+8.1%)

3% less funds holding

Funds holding: 221 → 214 (-7)

12% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 41

22% less capital invested

Capital invested by funds: $2.32B → $1.82B (-$504M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
214
Holders Change
-7
Holders Change %
-3.17%
% of All Funds
3.09%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
36
Increased
73
Reduced
62
Closed
41
Calls
$16.6M
Puts
$7.11M
Net Calls
+$9.45M
Net Calls Change
+$24.8M

Top Buyers

1
AVM
Arch Venture Management
Illinois
+$134M
2
FCM
Farallon Capital Management
California
+$83.5M
3
First Trust Advisors
First Trust Advisors
Illinois
+$36.4M
4
BlackRock
BlackRock
New York
+$22.8M
5
Deutsche Bank
Deutsche Bank
Germany
+$19.7M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$81.5M
2
DGM
Darwin Global Management
Jersey
-$70M
3
AIM
ARK Investment Management
Florida
-$13.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$12M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
-$7.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Baillie Gifford & Co
26
Baillie Gifford & Co
United Kingdom
$14.6M -$3.16M -128,754 -17%
Charles Schwab
27
Charles Schwab
California
$13.9M +$344K +13,994 +2%
Jane Street
28
Jane Street
New York
$10.5M +$6.84M +278,399 +162%
UBS AM
29
UBS AM
Illinois
$9.83M +$2.98M +121,223 +41%
Norges Bank
30
Norges Bank
Norway
$9.63M +$2.85M +116,108 +39%
Voloridge Investment Management
31
Voloridge Investment Management
Florida
$8.97M +$3.6M +146,608 +62%
Bank of America
32
Bank of America
North Carolina
$8.48M +$1.01M +41,085 +13%
AI
33
Alphabet Inc
California
$7.54M – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$6.74M -$57K -2,319 -0.8%
TCM
35
Tang Capital Management
California
$6.33M +$6.63M +270,000 New
RSCM
36
Rock Springs Capital Management
Maryland
$5.86M +$2.52M +102,413 +69%
Ameriprise
37
Ameriprise
Minnesota
$5.39M +$31.1K +1,267 +0.6%
N
38
Nuveen
North Carolina
$4.33M +$256K +10,405 +6%
TD Asset Management
39
TD Asset Management
Ontario, Canada
$4.12M +$324K +13,200 +8%
Mirae Asset Global ETFs Holdings
40
Mirae Asset Global ETFs Holdings
Hong Kong
$4.08M +$4.28M +174,180 New
Russell Investments Group
41
Russell Investments Group
United Kingdom
$3.97M +$632K +25,733 +18%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$3.88M +$2.07M +84,134 +103%
Rafferty Asset Management
43
Rafferty Asset Management
New York
$3.87M -$1.94M -79,090 -32%
UBS Group
44
UBS Group
Switzerland
$3.81M -$2.15M -87,664 -35%
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$3.68M +$3.71M +151,066 New
SPS
46
Susquehanna Portfolio Strategies
Pennsylvania
$3.39M – – –
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.21M +$793K +32,279 +31%
Swiss National Bank
48
Swiss National Bank
Switzerland
$3.2M – – –
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$3.11M +$579K +23,565 +22%
Two Sigma Investments
50
Two Sigma Investments
New York
$2.83M -$5.85M -238,033 -66%
1
2
3 4 5

BEAM Hedge Fund Activity: Q2 2024 in Review

214 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2024, worth a combined $1.82B — down 22% from $2.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of BEAM and 36 opened new positions — a net loss of 5 holders — while 62 trimmed existing stakes and 73 added.

The largest buyer was Arch Venture Management, opening a new position worth an estimated $134M. The largest seller was Morgan Stanley, cutting an estimated $81.5M.

  • 214 institutional investors held Beam Therapeutics (BEAM) as of Q2 2024, down from 221 in Q1 2024.
  • Funds reported $1.82B of Beam Therapeutics stock for Q2 2024, down 22% quarter-over-quarter.
  • 36 funds opened new Beam Therapeutics positions in Q2 2024 and 41 closed out, a net change of -5 holders.
  • The largest Beam Therapeutics buyer in Q2 2024 was Arch Venture Management, an estimated $134M added.
  • The largest Beam Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $81.5M sold.

Based on aggregated 13F filings for Q2 2024.